These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26965145)

  • 1. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.
    Malorni L; Giuliano M; Migliaccio I; Wang T; Creighton CJ; Lupien M; Fu X; Hilsenbeck SG; Healy N; De Angelis C; Mazumdar A; Trivedi MV; Massarweh S; Gutierrez C; De Placido S; Jeselsohn R; Brown M; Brown PH; Osborne CK; Schiff R
    Mol Cancer Res; 2016 May; 14(5):470-81. PubMed ID: 26965145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative Dynamics of AR and ER Activity in Breast Cancer.
    D'Amato NC; Gordon MA; Babbs B; Spoelstra NS; Carson Butterfield KT; Torkko KC; Phan VT; Barton VN; Rogers TJ; Sartorius CA; Elias A; Gertz J; Jacobsen BM; Richer JK
    Mol Cancer Res; 2016 Nov; 14(11):1054-1067. PubMed ID: 27565181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of proliferation of estrogen receptor‑positive MCF‑7 human breast cancer cells by tamoxifen through c‑Jun transcription factors.
    Xu Y; Zou ST; Zhu R; Li W; Gu CW; Wei SH; Xie JM; Wu HR
    Mol Med Rep; 2013 Apr; 7(4):1283-7. PubMed ID: 23404426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
    Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
    BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen.
    Altundag K; Altundag O; Gunduz M; Arun B
    Med Hypotheses; 2004; 63(5):823-6. PubMed ID: 15488654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
    Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
    Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
    Nardone A; Weir H; Delpuech O; Brown H; De Angelis C; Cataldo ML; Fu X; Shea MJ; Mitchell T; Veeraraghavan J; Nagi C; Pilling M; Rimawi MF; Trivedi M; Hilsenbeck SG; Chamness GC; Jeselsohn R; Osborne CK; Schiff R
    Br J Cancer; 2019 Feb; 120(3):331-339. PubMed ID: 30555156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
    Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
    Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo.
    Faridi J; Wang L; Endemann G; Roth RA
    Clin Cancer Res; 2003 Aug; 9(8):2933-9. PubMed ID: 12912939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide analysis reveals a role for TDG in estrogen receptor-mediated enhancer RNA transcription and 3-dimensional reorganization.
    Kolendowski B; Hassan H; Krstic M; Isovic M; Thillainadesan G; Chambers AF; Tuck AB; Torchia J
    Epigenetics Chromatin; 2018 Jan; 11(1):5. PubMed ID: 29378668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
    Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
    Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.
    Liu Y; Ludes-Meyers J; Zhang Y; Munoz-Medellin D; Kim HT; Lu C; Ge G; Schiff R; Hilsenbeck SG; Osborne CK; Brown PH
    Oncogene; 2002 Oct; 21(50):7680-9. PubMed ID: 12400010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
    Tomlinson DC; Knowles MA; Speirs V
    Int J Cancer; 2012 Jun; 130(12):2857-66. PubMed ID: 21792889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.